You have 9 free searches left this month | to do more
Showing 1 - 25 of
1,470 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
K
Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS
Recruiting
  • Preleukemia
  • +2 more
  • Copenhagen, Copenhagen N, Denmark
    Rigshospitalet
2022-01-20
Jan 20, 2022
N
BMS-986253 in Myelodysplastic Syndromes
Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
A
Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes - 2015
Completed
  • Myelodysplastic Syndromes
    • (no location specified)
    2022-01-21
    Jan 21, 2022
    T
    Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes
    No longer available
    • Myelodysplastic Syndromes
    • (no location specified)
    2021-09-08
    Sep 8, 2021
    F
    A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome
    Withdrawn
    • Myelodysplastic Syndrome (MDS)
    • (no location specified)
    2021-07-20
    Jul 20, 2021
    C
    Revlimid in Transfusion Dependent Patients
    Active, not recruiting
    Has Results
    • Myelodysplastic Syndrome
    • Revlimid (Lenalidomide)
    • New York, New York
      Columbia University Medical Center
    2022-01-12
    Jan 12, 2022
    R
    Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
    Not yet recruiting
    • Low Risk Myelodysplastic Syndromes
    • R906289 Monosodium (R289 Na)
    • (no location specified)
    2022-03-25
    Mar 25, 2022
    D
    The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study - 2020
    Completed
    • Myelodysplastic Syndromes (MDS)
      • Boston, Massachusetts
      • +2 more
      2022-02-28
      Feb 28, 2022
      N
      Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia
      Recruiting
      • Myelodysplasia
      • Hematologic Malignancy
      • CliniMACS® TCRαβ/CD19 Combined Depletion System
      • Columbus, Ohio
        Nationwide Children's Hospital
      2022-01-11
      Jan 11, 2022
      W
      Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
      Active, not recruiting
      • Myelodysplastic Syndromes
      • Saint Louis, Missouri
        Washington University School of Medicine
      2022-03-23
      Mar 23, 2022
      M
      Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
      Active, not recruiting
      • High Risk Myelodysplastic Syndrome
      • Houston, Texas
        M D Anderson Cancer Center
      2022-02-02
      Feb 2, 2022
      O
      Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes
      Active, not recruiting
      • Lower-risk Myelodysplastic
      • Tokyo, Japan
        NTT Medical Center Tokyo
      2022-01-14
      Jan 14, 2022
      U
      Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
      Recruiting
      • High Grade Myelodysplastic Syndromes
      • Aurora, Colorado
        Universtiy of Colorado Denver
      2021-10-19
      Oct 19, 2021
      T
      Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly
      Recruiting
      • Myelodysplastic Syndromes
      • Observational
      • Dresden, Germany
      • +1 more
      2021-08-10
      Aug 10, 2021
      T
      A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
      Withdrawn
      • Myelodysplastic Syndromes (MDS)
      • (no location specified)
      2021-09-23
      Sep 23, 2021
      D
      Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS - 2021
      Completed
      • Myelodysplastic Syndromes
      • Peri-Transfusion QOL Assessment
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      2022-01-06
      Jan 6, 2022
      A
      A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
      Recruiting
      • Myelodysplastic Syndrome
      • Suzhou, Jiangsu, China
        The First Affiliated Hospital of Soochow University
      2021-07-21
      Jul 21, 2021
      U
      A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
      Active, not recruiting
      • Myelodysplastic Syndromes
      • Chronic Myelomonocytic Leukemia
      • Rochester, New York
        University of Rochester
      2022-01-04
      Jan 4, 2022
      S
      SNS-301 Monotherapy in High Risk MDS and CMML
      Withdrawn
      • Myelodysplastic Syndromes
      • Chronic Myelomonocytic Leukemia (CMML)
      • (no location specified)
      2021-08-09
      Aug 9, 2021
      Y
      CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure. - 2021
      Withdrawn
      • MDS
      • New Haven, Connecticut
        Yale University; Smilow Cancer Center
      2022-01-06
      Jan 6, 2022
      P
      RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT
      Recruiting
      • Myelodysplastic Syndromes
      • Beijing, Beijing, China
        Peking University Institute of Hematology,Beijing
      2021-09-14
      Sep 14, 2021
      N
      Biology Studies of Hematologic Cancers
      Enrolling by invitation
      • Acute Lymphoblastic Leukemia
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        2022-04-07
        Apr 7, 2022
        S
        Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
        Suspended
        • Myelodysplastic Syndromes
        • Allogeneic umbilical cord mesenchymal stem cells
        • Decitabine
        • Hohhot, Inner Mongolia, China
          Inner Mongolia International Mongolian Hospital
        2022-02-14
        Feb 14, 2022
        U
        Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
        Recruiting
        • Myelodysplasia
        • Grenoble, France
          CHU de GRENOBLE ALPES
        2021-10-01
        Oct 1, 2021
        A
        AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
        Not yet recruiting
        • Higher Risk Myelodysplastic Syndrome
        • Chronic Myelomonocytic Leukemia
        • (no location specified)
        2022-01-13
        Jan 13, 2022